Tickers — V

49 tickers
Ranks this page's recent reports by score.
Veralto Corporation
VLTO·Industrials
A ★★★★Buy
Current$111.10
Target$117.60
Return+5.9%
Nov 1, 2026

Veralto combines durable water-quality demand, recurring industrial consumables and high returns on capital, but its premium valuation and acquisition integration requirements constrain the margin of safety.

Score
79
Vistance Networks, Inc.
VISN·Technology
C ★★Sell
Current$6.54
Nov 1, 2026

Vistance Networks offers a substantially deleveraged broadband equipment turnaround with potential margin recovery, but deteriorating core EBITDA, uncertain cash conversion, and post-divestiture execution risks weaken its investment appeal.

Score
56
V.F. Corporation
VFC·Consumer Discretionary
B ★★★Hold
Current$18.30
Target$19.32
Return+5.6%
Nov 1, 2026

V.F. Corporation offers a credible margin and cash-flow turnaround supported by The North Face and Timberland, but persistent Vans weakness and substantial debt limit confidence in sustained earnings recovery.

Score
68
Virtu Financial, Inc.
VIRT·Financials
B ★★★Hold
Current$53.76
Target$65.00
Return+20.9%
Nov 1, 2026

Virtu Financial combines scalable electronic market-making technology, high capital returns, and attractive earnings multiples, but its long-term valuation depends on whether elevated trading profitability survives market normalization.

Score
73
Vulcan Materials Company
VMC·Materials
B ★★★Hold
Current$281.25
Target$294.06
Return+4.6%
Nov 1, 2026

Vulcan Materials' scarce quarry assets and resilient pricing power support long-term earnings compounding, but its premium valuation and cyclical construction demand limit the margin of safety.

Score
71
Verisk Analytics, Inc.
VRSK·Industrials
A ★★★★Buy
Current$196.30
Target$213.75
Return+8.9%
Nov 1, 2026

Verisk combines a durable insurance data moat, exceptional cash conversion, and a historically discounted valuation, although the unresolved AccuLynx acquisition threatens financial flexibility and capital-allocation returns.

Score
81
Viking Therapeutics, Inc.
VKTX·Healthcare
F Avoid
Current$27.28
Oct 31, 2026

Viking Therapeutics could establish a valuable obesity-drug franchise through injectable and oral VK2735, but its lack of revenue, substantial cash burn, and dependence on successful Phase 3 trials create significant investment risk.

Score
42
Veracyte, Inc.
VCYT·Healthcare
B ★★★Hold
Current$50.01
Target$57.74
Return+15.5%
Oct 31, 2026

Veracyte combines growing genomic cancer testing demand, improving margins, and strong cash generation with promising new oncology products, but premium valuation and reimbursement dependence constrain near-term upside.

Score
68
VSE Corporation
VSEC·Industrials
B ★★★Hold
Current$147.83
Target$181.72
Return+22.9%
Oct 31, 2026

VSE can compound aviation aftermarket earnings through specialized repairs, OEM partnerships, and PAG integration, but acquisition-related dilution and weak free cash conversion threaten shareholder returns.

Score
65
Vista Energy, S.A.B. de C.V.
VIST·Energy
A ★★★★Buy
Current$70.45
Target$85.50
Return+21.4%
Oct 31, 2026

Vista Energy offers profitable, rapid Vaca Muerta shale production growth at modest earnings multiples, but oil-price volatility, capital-intensive development, and Argentina policy exposure remain material risks.

Score
80
Vertiv Holdings Co
VRT·Industrials
A ★★★★Buy
Current$232.50
Target$277.50
Return+19.4%
Oct 31, 2026

Vertiv is a leading supplier of AI data-center power and cooling infrastructure, combining accelerating organic growth with strong cash generation, although demanding valuation and hyperscaler capital-spending volatility remain key concerns.

Score
79